In a year-long phase II trial, Ambroxol, a widely used cough medicine in Europe, showed target engagement in patients with ...

Treatment with ambroxol for symptoms of Parkinson’s disease dementia was safe, but its efficacy was undetermined in a small ...

Looking a treatment for symptoms of decline in thinking and reasoning skills? Recent study approves common cough syrup to ...

Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

A safe and affordable treatment to slow the advancement of Parkinson's dementia has emerged – in the form of a commonly ...

In a small clinical trial in Canada, a medicine commonly found in European cough syrups has shown early signs it might do ...

Ambroxol, a cough medication, may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, a new study ...

A recent phase 2 clinical trial reveals that Ambroxol, a common cough medicine, shows promise in stabilizing psychiatric symptoms and potentially slow ...

Ambroxol increased enzyme levels in Parkinson’s dementia patients, but showed no cognitive benefit in a year-long trial.

Now, a new year-long clinical trial suggests that the cough medicine Ambroxol – used safely for decades in Europe – can potentially slow the development of these symptoms.

The Phase III trial will enroll over 300 people with Parkinson's disease, some of whom will receive the cough drug ambroxol.